Linated proteins, but did not cause additional inflammation in mice nor
Linated proteins, but did not cause additional inflammation in mice nor did it PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28914615 cause an immune response PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28607003 to citrullinated proteins. Generating anti-CCP-positive mice will be crucial in studying the effect of specific immune complexes on arthritic phenomena in mouse models of arthritis. Acknowledgements This work was financially supported by the Netherlands Foundation for Chemical Research and the Netherlands Technology Foundation, the Dutch League against Rheumatism and the Netherlands Foundation for Medical Research.P46 Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritisJD Isaacs1, AM Clarke2, BL Hazleman3, G Hale4, H Waldmann4, DPM Symmons2 1School of Clinical Medical Sciences, University of Newcastle upon Tyne, UK; 2ARC Epidemiology Unit, University of Manchester, UK; 3Department of Rheumatology, Addenbrooke’s Hospital NHS Trust, Cambridge, UK; 4Dunn School of Pathology, University of Oxford, UK Arthritis Res Ther 2005, 7(Suppl 1):P46 (DOI 10.1186/ar1567) Background In the early 1990s, we used the monoclonal antibody alemtuzumab (MabCampath, Schering AG, Berlin, Germany) to treat patients with refractory rheumatoid arthritis. This treatment provided temporary relief of symptoms but was associated with long-term lymphopenia, particularly of T lymphocytes [1]. We continue to follow these patients to exclude any adverse effects of their longterm lymphopenia. Objective The objective of the current study was to compare 10-year mortality in this patient cohort with mortality in a control patient cohort. Methods Fifty-three rheumatoid arthritis patients that received alemtuzumab (median dose, 172 mg; range, 1?20 mg) between 1991 and 1994 (cases) were monitored via the Office for National Statistics Central Registry, to ensure notification of death. A retrospective, matched-cohort study of mortality was performed with 102 control subjects selected from the European League Against Rheumatism database. This database comprises patients with rheumatic disorders who have received immunosuppressive drugs, usually cyclophosphamide or azathioprine. Results Median (range) duration of follow-up was 10.29 (1.27?2.15) years for cases and 10.35 (1.18?2.14) years for controls. There were 20 deaths among the cases compared with 37 among the controls. This provided a mortality rate of 0.045 deaths per person per year for the cases and 0.041 deaths per person per year for the controls. The mortality rate ratio was 1.10 (95 confidence interval, 0.61?.95). There was no significant difference in survival between the two groups (P = 0.73, log-rank test). Figure 1 illustrates Kaplan eier survival plots for cases and controls. The causes of death in the cases reflected those expected in a hospital-based rheumatoid arthritis cohort. Median time (range) from treatment to death for cases was 5.9 (1.3?1.7) years. Mortality did not differ according to total dose of alemtuzumab or the number of courses received. Conclusions Despite long-term lymphopenia, there was no excess mortality in recipients of alemtuzumab at a median follow-up of 10.3 years from treatment. Reference 1. Isaacs JD, Greer S, Sharma S, Symmons D, Smith M, Johnston J, Waldmann H, Hale G, Hazleman BL: Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound purchase Quizartinib therapy-induced lymphopenia. Arthritis Rheum 2001, 44:1998-2008. Acknowledgements This work was supported by Ilex Oncology, Inc. and the Arthritis Research CampaignP45 Effects of.
Posted inUncategorized